Literature DB >> 8946648

The beneficial effect of taurine on the prevention of human endothelial cell death.

J H Wang1, H P Redmond, R W Watson, C Condron, D Bouchier-Hayes.   

Abstract

This study was designed to test the hypothesis that the antioxidant taurine may modulate human endothelial cell (EC) death (apoptosis versus necrosis). Sodium arsenite (80 microM) alone and in combination with tumor necrosis factor-alpha (25 ng/mL) caused EC apoptosis after 24 h of treatment. Taurine (.5 mg/mL) added at 0 and 6 h could significantly attenuate EC apoptosis, and oxidative state in response to lipopolysaccharide and tumor necrosis factor-alpha stimulation. EC necrosis was induced by activated neutrophils (PMNs). Taurine reduced PMN-mediated EC necrosis in a dose-dependent manner. Moreover, treatment of ECs with a calcium ionophore, A23187 (1.0-4.0 microM), resulted in both EC apoptosis and necrosis. Taurine significantly abrogated A23187-mediated intracellular calcium elevation and EC death. These data indicate that taurine, possibly through its antioxidant activity and regulation of intracellular calcium flux, can prevent EC dysfunction and cell death, which may have implications for the application of this amino acid in the amelioration of acute lung injury during systemic inflammatory response syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8946648     DOI: 10.1097/00024382-199611000-00006

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  10 in total

1.  Taurine attenuates CD3/interleukin-2-induced T cell apoptosis in an in vitro model of activation-induced cell death (AICD).

Authors:  S G Maher; C E M Condron; D J Bouchier-Hayes; D M Toomey
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

2.  Role of taurine in the vasculature: an overview of experimental and human studies.

Authors:  Worku Abebe; Mahmood S Mozaffari
Journal:  Am J Cardiovasc Dis       Date:  2011-09-10

3.  Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma.

Authors:  G C O'Brien; R A Cahill; D J Bouchier-Hayes; H P Redmond
Journal:  Ir J Med Sci       Date:  2006 Jan-Mar       Impact factor: 1.568

4.  Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model.

Authors:  N Finnegan; D Toomey; C Condron; H P Redmond; M Da Costa; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  2002 Apr-Jun       Impact factor: 1.568

5.  Taurine attenuates radiation-induced lung fibrosis in C57/Bl6 fibrosis prone mice.

Authors:  W B Robb; C Condron; M Moriarty; T N Walsh; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  2009-07-16       Impact factor: 1.568

6.  Neuroprotection by taurine in ethanol-induced apoptosis in the developing cerebellum.

Authors:  Andrey G Taranukhin; Elena Y Taranukhina; Pirjo Saransaari; Irina M Podkletnova; Markku Pelto-Huikko; Simo S Oja
Journal:  J Biomed Sci       Date:  2010-08-24       Impact factor: 8.410

7.  Taurine modulates neutrophil function but potentiates uropathogenic E. coli infection in the murine bladder.

Authors:  Claire Condron; Rowan G Casey; Siobhan Kehoe; Deirdre Toomey; Tom Creagh; David J Bouchier-Hayes
Journal:  Urol Res       Date:  2009-11-26

8.  Neutrophil bactericidal function is defective in patients with recurrent urinary tract infections.

Authors:  C Condron; D Toomey; R G Casey; M Shaffii; T Creagh; D Bouchier-Hayes
Journal:  Urol Res       Date:  2003-07-31

9.  Effect of maternal low-protein diet and taurine on the vulnerability of adult Wistar rat islets to cytokines.

Authors:  S Merezak; B Reusens; A Renard; K Goosse; L Kalbe; M T Ahn; J Tamarit-Rodriguez; C Remacle
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

Review 10.  Atherosclerosis Linked to Aberrant Amino Acid Metabolism and Immunosuppressive Amino Acid Catabolizing Enzymes.

Authors:  Bozidarka L Zaric; Jelena N Radovanovic; Zoran Gluvic; Alan J Stewart; Magbubah Essack; Olaa Motwalli; Takashi Gojobori; Esma R Isenovic
Journal:  Front Immunol       Date:  2020-09-28       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.